Welcome to the pain marketplace. You must hold a decision-making position at Xano.
Zipsor is not a crappy drug - but it is also nothing special. I know doctors involved in unpublished studies who shared with me that Zipsor is less powerful than ibuprofen in dental studies. I'm talking OTC strength. Exactly how does Zipsor compare to other nsaids as far as efficacy and clinical speed to relief? Careful, the FDA may be reading. Detail any CLINICAL data that shows ANY superior outcomes relative to the class. Please suggest that reps compare PI's to extrapolate that Zipsor is better tolerated, quicker, or offers greater analgesia based on the delivery system and the resultant PK data. These directives, when unearthed, are what often spur the FDA to mandate "Dear Dr" letters.
Also, it seems like you might not understand the significance of chronic pain vs. acute pain as it applies to market potential. Don't take it personally. The company's sales forecasting was also out to lunch on this topic.
Then there is this thing called managed care coverage. Were you aware that diclofenac has many formulations, most of them generic? Were you aware that most NSAIDS are bought OTC or prescribed generic? Do you know what the terms "step-edit", "closed formulary", and"prior authorization" mean? How about the concept of launching an over-priced branded reformulated product in a crowded, established, and largely generic marketplace during one of this country's worst economic recessions? Don't worry; you'll soon have lots of free time to mull these terms and concepts over.
As for davocet. The FDA recommended that all propoxyphene be pulled. It was not a directive. Many of my pharmacies still stock variations of propoxyphene. The FDA may likely ban this molecule. But they haven’t yet. Don't believe me? Talk to a pharmacy or Google the topic.
My new job starts soon. Thanks for the second paycheck. Hope everyone joins me- I know that some of you are!
Happy Holidays!
Double-dipper!